MedPage Today, August 1, 2024: When the company that makes Wegovy weight loss drugs say it reduces major cardiovascular events by 20% they really mean it reduces that risk by 1.5% for each patient. That’s because only 8% of the placebo group had major cardiovascular events, compared to 6.5% of the Wegovy patients. Isn’t that misleading? We explain why most weight loss patients will not benefit in terms of heart disease, because the benefit is small and requires staying on Wegovy for almost 3 years.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
NCHR and Consumer Groups Applaud Decision to Hold Amazon Responsible for Certain Hazardous Products
July 30, 2024: NCHR and other consumer groups’ joint press release expresses their support for the CPSC decision to hold Amazon responsible for certain hazardous products sold by third parties on their website. According to the Decision and Order, Amazon is a “distributor” of certain defective or non-compliant products and is therefore responsible for the illegal sale of those products. Amazon must submit plans to notify consumers about specific hazardous products and offer incentives to return or destroy the products.
Read More »Open Letter to the FDA: You’re Protecting the Wrong People
MedShadow, July 23, 2024: We agree with Medshadow that it is outrageous that the FDA is warning companies about fraudulent tests that mean their medications may not be safe or effective but are not warning patients who are buying these medications.
Read More »Revolving door: You are free to influence us “behind the scenes,” FDA tells staff leaving for industry jobs
BMJ, July 1, 2024: BMJ investigation reveals how revolving door and FDA Ethics office allow former FDA staff to lobby for industry and Dr. Diana Zuckerman explains how this creates conflicts of interest that undermine FDA decision-making.
Read More »Advisory Committee Consumer Reps Often Fail To Represent Consumer Interests, Groups Tell US FDA
Pink Sheet, June 13, 2024: NCHR quoted from FDA listening session on optimizing the advisory committee process.
Read More »